Landmark BioVentures (LBV), an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies, and G.CLIPS Biotech, a technology platform company changing the paradigm in targets by enabling the discovery, generation and validation of conformation-sensitive and pathology-sensitive drug candidates, have announced a strategic alliance.

The partnership addresses a critical gap in early-stage drug development, where target engagement and physiopathology – a cornerstone of therapeutic efficacy and safety – are often underestimated, due to technical, financial and/or strategic constraints. Addressing this gap early helps to de-risk the overall drug development process, gaining significant efficiencies, with both time and cost savings, the company said in a statement.

This agreement deepens the existing collaboration between LBV and G.CLIPS, founded on shared scientific and strategic values, which started in 2023.

LBV has validated G.CLIPS’ innovative platform first-hand, demonstrating the ability of the technology to provide novel, cost-effective solutions for target engagement and candidate profiling to address critical gaps in early-stage drug development.

By formalising this partnership, G.CLIPS now becomes a long-term partner in LBV’s innovation ecosystem, supporting lead candidate nomination, deepening the understanding of specific therapeutic mechanisms of action and defining the target product profile of drug candidates.

Zaki Sellam, co-founder and CEO of Landmark BioVentures said, “Target engagement isn’t just a box to check; it is the cornerstone of successful drug development. This strategic alliance with G.CLIPS equips our nexus of companies with tools that were previously inaccessible, turning a traditional bottleneck into a strategic advantage.”

Rosie Dawaliby, co-founder and CEO at G.CLIPS Biotech commented, “We’re excited to deploy our unique technology platform across LBV’s nexus through this alliance. LBV’s integrative model aligns perfectly with our approach, allowing us to demonstrate G.CLIPS’ value as an embedded strategic partner in drug development programs.”

She further added, “This collaboration provides the ideal opportunity to showcase the versatility of our target engagement and candidates, profiling solutions while creating significant potential for deeper involvement in LBV’s development pipeline.”